Impact of ovarian stimulation on corpus luteum function and embryonic implantation

Tavaniotou, Asimina; Albano, Carola; Smitz, Johan; Devroey, Paul

doi:10.1016/s0165-0378(01)00134-6

Cited by 108 publications

(53 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is biological plausibility and clinical evidence to suggest that exogenous gonadotropins and clomiphene citrate may have differing effects on endogenous luteal phase function. The effect of exogenous gonadotropins directly on the ovaries leads to increased serum estradiol and negative feedback on the hypothalamic-pituitary--ovarian axis (Messinis, 2006,Tavaniotou et al, 2002,Tavaniotou et al, 2001), leading to aberrant LH pulsatility and progesterone secretion (Rossmanith et al, 1990). This feedback loop has been proposed as a mechanism of luteal phase dysfunction in gonadotropin-stimulated cycles (Tavaniotou et al, 2002,Tavaniotou et al, 2001,Hill et al, 2013.…”

Section: Discussionmentioning

confidence: 99%

Progesterone-releasing vaginal ring for luteal phase support after superovulation and intrauterine insemination cycles, a pilot study

Schwarze¹,

Villa²,

Manzur³

et al. 2013

JBRA Assisted Reproduction

View full text Add to dashboard Cite

Objective: The main objective of this pilot study was to determine whether a progesterone-releasing vaginal ring is a good alternative for luteal phase support for patients undergoing intrauterine insemination after ovulation induction with sc gonadotrophins. material and methods: We performed a multi-center study involving three different reproductive medicine units. Patients included were diagnosed with unexplained infertility rFSH (Puregon ®) and ovulation induction with urinary HCG (Pregnyl ®). The day of insemination patients were randomized to receive luteal phase supplementation with progesterone vaginal ring (Fertiring ®) or no supplementation.

show abstract

Section: Discussionmentioning

confidence: 99%

Progesterone-releasing vaginal ring for luteal phase support after superovulation and intrauterine insemination cycles, a pilot study

Schwarze¹,

Villa²,

Manzur³

et al. 2013

JBRA Assisted Reproduction

View full text Add to dashboard Cite

show abstract

“…Although our data was retrospective, uniform dose and route of administration of GnRH agonist and uniform luteal support combination with progesterone made comparison of the groups more reliable. Because the number of transferred embryos and Grade I embryo numbers were different between the groups, we performed subgroup analysis (Table 4, 5). By these analyses, we aimed to alleviate the confounding heterogeneity between the groups with respect to the number of both transferred embryos and Grade I embryos.…”

Section: Total Cycles N=9470mentioning

confidence: 99%

“…However, supraphysiological steroid hormone levels together with the suppressed luteinizing hormone (LH) levels by both GnRH agonist and GnRH antagonist administration during COH cycles lead to a defect in the luteal phase, particularly in in vitro fertilization (IVF) cycles (3)(4)(5)(6)(7)(8). Therefore, use of medication for luteal phase support (LPS) has been considered to be mandatory to ensure intact corpus luteum function and to avoid any decrease in implantation and pregnancy rates (7,9).…”

Section: Introductionmentioning

confidence: 99%

Addition of gonadotropin releasing hormone agonist for luteal phase support in in-vitro fertilization: an analysis of 2739 cycles

Şimşek

Kılıçdağ

Aytaç

et al. 2015

J Turkish German Gynecol Assoc

View full text Add to dashboard Cite

Objective: Luteal phase is defective in in vitro fertilization (IVF) cycles, and many regimens were tried for the very best luteal phase support (LPS). Gonadotropin releasing hormone (GnRH) agonist use, which was administered as an adjunct to the luteal phase support in IVF cycles, was suggested to improve pregnancy outcome measures in certain randomized studies. We analyzed the effects of addition of GnRH agonist to standard progesterone luteal support on pregnancy outcome measures, particularly the live birth rates. Material and Methods:This is a retrospective cohort study, including 2739 IVF cycles. Long GnRH agonist and antagonist stimulation IVF cycles with cleavage-stage embryo transfer were included. Cycles were divided into two groups: Group A included cycles with single-dose GnRH agonist plus progesterone LPS and Group B included progesterone only LPS. Live birth rates were the primary outcome measures of the analysis. Miscarriage rates and multiple pregnancy rates were the secondary outcome measures.Results: Live birth rates were not statistically different in GnRH agonist plus progesterone (Group A) and progesterone only (Group B) groups in both the long agonist and antagonist stimulation arms (40.8%/41.2% and 32.8%/34.4%, p<0.05 respectively). Moreover, pregnancy rates, implantation rates, and miscarriage rates were found to be similar between groups. Multiple pregnancy rates in antagonist cycles were significantly higher in Group A than those in Group B (12.0% and 6.9%, respectively). Conclusion:A beneficial effect of a single dose of GnRH agonist administration as a luteal phase supporting agent is yet to be determined because of the wide heterogeneity of data present in literature. Well-designed randomized clinical studies are required to clarify any effect of luteal GnRH agonist addition on pregnancy outcome measures with different doses, timing, and administration routes of GnRH agonists. (J Turk Ger Gynecol Assoc 2015; 16: 96-101) Keywords: GnRH agonist, luteal phase support, in vitro fertilization (IVF), progesterone Received: 23 February, 2015 Accepted: 06 April, 2015 Addition of gonadotropin releasing hormone agonist for luteal phase support in in-vitro fertilization: an analysis of 2739 cycles Abstract secretion were some of the proposed potential mechanisms of actions (13,14). The purpose of this study was to evaluate whether the addition of single-dose GnRH agonist to the progesterone for luteal support in IVF cycles improves the pregnancy outcome measures, particularly the live birth rates. Material and Methods Study design and study populationThis study was a retrospective study conducted at

show abstract

“…pregnancies (%) [34,50] can disturb endocrine profiles causing an aberrant follicular, oviductal or uterine environment and disruptions in oocyte maturation, embryo development, or implantation [78][79][80]. Safety also can be an issue with eCG and hCG as these are large, foreign glycoproteins that persist for days in circulation and can induce gonadotropin-neutralizing antibodies after subsequent eCG/hCG treatments [74,81,82].…”

Section: Gonadotropinsmentioning

confidence: 99%

Approaches and efficacy of artificial insemination in felids and mustelids

2009

View full text Add to dashboard Cite

Impact of ovarian stimulation on corpus luteum function and embryonic implantation

Cited by 108 publications

References 27 publications

Progesterone-releasing vaginal ring for luteal phase support after superovulation and intrauterine insemination cycles, a pilot study

Progesterone-releasing vaginal ring for luteal phase support after superovulation and intrauterine insemination cycles, a pilot study

Addition of gonadotropin releasing hormone agonist for luteal phase support in in-vitro fertilization: an analysis of 2739 cycles

Approaches and efficacy of artificial insemination in felids and mustelids

Contact Info

Product

Resources

About